# Spectral AI, Inc.: overview MDAI · Nasdaq · CIK 1833498 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mdai.md) · [Financials](/companies/mdai/financials.md) · [Filings](/companies/mdai/filings.md) · [Insiders](/companies/mdai/insiders.md) Latest reported revenue: [$3.5m](/filings/0001213900-26-087764.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-087764). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [8,173](/filings/0001213900-25-109409.md) | [7,604 d](/filings/0001213900-26-033808.md) | [6,707](/filings/0001213900-26-055226.md) | [5,065](/filings/0001213900-26-087764.md) | [3,792](/filings/0001213900-25-109409.md) | [4,086 d](/filings/0001213900-26-033808.md) | [3,991](/filings/0001213900-26-055226.md) | [3,524](/filings/0001213900-26-087764.md) | | Gross margin | % | [44.9%](/filings/0001213900-25-109409.md) | [44.0% d](/filings/0001213900-26-033808.md) | [47.2%](/filings/0001213900-26-055226.md) | [45.2%](/filings/0001213900-26-087764.md) | [42.7%](/filings/0001213900-25-109409.md) | [45.2% d](/filings/0001213900-26-033808.md) | [50.8%](/filings/0001213900-26-055226.md) | [31.6%](/filings/0001213900-26-087764.md) | | Operating margin | % | [(10.8%)](/filings/0001213900-25-109409.md) | [(14.6%) d](/filings/0001213900-26-033808.md) | [(13.4%)](/filings/0001213900-26-055226.md) | [(41.9%)](/filings/0001213900-26-087764.md) | [(88.1%)](/filings/0001213900-25-109409.md) | [(54.9%) d](/filings/0001213900-26-033808.md) | [(49.4%)](/filings/0001213900-26-055226.md) | [(122.7%)](/filings/0001213900-26-087764.md) | | Net margin | % | [(18.4%)](/filings/0001213900-25-109409.md) | [(99.8%) d](/filings/0001213900-26-033808.md) | [43.2%](/filings/0001213900-26-087764.md) | [(157.3%)](/filings/0001213900-26-087764.md) | [(93.7%)](/filings/0001213900-25-109409.md) | [25.7% d](/filings/0001213900-26-033808.md) | [(85.5%)](/filings/0001213900-26-087764.md) | [(118.5%)](/filings/0001213900-26-087764.md) | | Diluted EPS | $ per share | [(0.08)](/filings/0001213900-25-109409.md) | not reported | [0.11](/filings/0001213900-26-055226.md) | [(0.31)](/filings/0001213900-26-087764.md) | [(0.13)](/filings/0001213900-25-109409.md) | not reported | [(0.11)](/filings/0001213900-26-055226.md) | [(0.13)](/filings/0001213900-26-087764.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [25.4](/filings/0001213900-24-027863.md) | [18.1](/filings/0001213900-25-026157.md) | [29.6](/filings/0001213900-26-033808.md) | [19.7](/filings/0001213900-26-033808.md) | | Gross margin | % | not reported | [42.7%](/filings/0001213900-24-027863.md) | [43.6%](/filings/0001213900-25-026157.md) | [44.9%](/filings/0001213900-26-033808.md) | [45.4%](/filings/0001213900-26-033808.md) | | Operating margin | % | not reported | [(10.4%)](/filings/0001213900-24-027863.md) | [(71.9%)](/filings/0001213900-25-026157.md) | [(22.3%)](/filings/0001213900-26-033808.md) | [(43.8%)](/filings/0001213900-26-033808.md) | | Net margin | % | not reported | [(11.5%)](/filings/0001213900-24-027863.md) | [(115.5%)](/filings/0001213900-25-026157.md) | [(51.2%)](/filings/0001213900-26-033808.md) | [(38.5%)](/filings/0001213900-26-033808.md) | | Diluted EPS | $ per share | not reported | [(0.22)](/filings/0001213900-24-027863.md) | [(1.48)](/filings/0001213900-25-026157.md) | [(0.85)](/filings/0001213900-26-033808.md) | [(0.29)](/filings/0001213900-26-033808.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mdai/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.7m | 994,410 | | Added +268,120 | | [Highlander Partners, L.P.](/funds/1903866.md) | 2026-06-30 | $1.6m | 900,000 | | Unchanged | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.4m | 827,454 | | New +827,454 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $496.5k | 287,000 | | Added +88,000 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $391.5k | 226,319 | | Added +5,318 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $390.7k | 225,823 | | Added +112,803 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $385.2k | 222,595 | | Reduced −78,612 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $279.9k | 161,777 | | Added +39,523 | | [LMR Partners LLP](/funds/1578621.md) | 2026-06-30 | $279.6k | 503,694 | | Added +196,185 | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $278.0k | 160,701 | | New +160,701 | ## Recent filings [All 297 filings](/companies/mdai/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-15 | 16:03 ET | [8-K](/filings/0001213900-26-100119.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-100119 | | 2026-08-12 | 16:03 ET | [8-K](/filings/0001213900-26-088341.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-088341 | | 2026-08-11 | 16:02 ET | [10-Q](/filings/0001213900-26-087764.md) | Quarterly report, period 2026-06-30 | 0001213900-26-087764 | | 2026-07-08 | 16:01 ET | [8-K](/filings/0001213900-26-076349.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-076349 | | 2026-06-01 | 16:01 ET | [8-K](/filings/0001213900-26-063486.md) | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-063486 | | 2026-05-26 | 16:00 ET | [8-K](/filings/0001213900-26-061008.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-061008 | | 2026-05-13 | 18:01 ET | [10-Q](/filings/0001213900-26-055226.md) | Quarterly report, period 2026-03-31 | 0001213900-26-055226 | | 2026-04-22 | 08:00 ET | [8-K](/filings/0001213900-26-046405.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-046405 | | 2026-04-16 | 16:05 ET | [DEF 14A](/filings/0001213900-26-044635.md) | Proxy statement, period 2026-05-29 | 0001213900-26-044635 | | 2026-04-08 | 16:00 ET | [8-K](/filings/0001213900-26-041479.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-041479 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-033808.md), filed Mar 25, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/797f1607-caef-44e8-898c-843550c4df0a) ## About the filer - CIK: 1833498 - Tickers: MDAI, MDAIW - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.